2,2-dimethyl-(3ar,6ac)-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-4-one | 18908-38-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-dimethyl-(3ar,6ac)-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-4-one
• 英文别名: (3aR,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-4-one
• CAS: 18908-38-8
• 化学式: C₇H₁₁NO₃
• 分子量: 157.169
• InChiKey: AKOYRYRJZZSFBU-RFZPGFLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-(3ar,6ac)-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-4-one 在 劳森试剂 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of (−)-8-deoxy-7-hydroxy-swainsonine and (±)-6,8-dideoxy-castanospermine

  摘要：

  A total synthesis of (1S,2R,7S,8aR)-1,2,7-trihydroxyindolizidine 3 has been achieved in few steps from lactam 4. The dihydroxyderivative 14 has also been PrePared with the same general synthetic approach adapting a Michael addition and a thioamide-diazoketone cyclocondensation as key steps.

  DOI：

  10.1016/s0040-4039(00)79036-8
• 作为产物：
  描述：

  D-erythronolactone acetonide 在 sodium azide 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 110.0~150.0 ℃ 、202.66 kPa 条件下， 反应 28.0h， 生成 2,2-dimethyl-(3ar,6ac)-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-4-one
  参考文献：
  名称：

  由手性和非手性聚乙烯吡咯烷酮稳定的双金属纳米团簇的合成和表征。催化 C(sp3)–H 氧化

  摘要：

  第二代手性取代的聚-N-乙烯基吡咯烷酮(CSPVPs) (-)- 1R和(+)- 1S通过(3a R ,6a R )- 和(3a S ,6a S )-的自由基聚合合成5-ethenyl-tetrahydro-2,2-dimethyl-4 H -1,3-dioxolo[4,5- c ]pyrrol-4-one，分别使用热和光化学反应。它们分别由d-异抗坏血酸和d-核糖生产。此外，手性聚合物(-)- 2也由( S )聚合合成。)-3-(甲氧基甲氧基)-1-vinylpyrrolidin-2-one。使用 HRMS 测量这些手性聚合物的分子量，并使用13 C NMR 光谱研究聚合物链的立构规整度。手性聚合物 (-)- 1R、 (+)- 1S和 (-)- 2以及聚-N-乙烯基吡咯烷酮 (PVP, MW 40K) 分别用于稳定 Cu/Au 或 Pd/Au 纳米团簇。(-)- 1R和(+)- 1S稳定的双金属纳米团簇的CD光谱在波长

  DOI：

  10.1021/acs.joc.2c00449

文献信息

• N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
  申请人：——

  公开号：US20040072830A1

  公开（公告）日：2004-04-15

  The present invention provides an excellent squalene synthase inhibitor. Specifically, it provides a compound (I) represented by the following formula, a salt thereof or a hydrate of them. 1 wherein R 1 represents an optionally substituted vinyl group or an aromatic ring which may be substituted; n is an integer of 0 to 2; X, Y and Z are the same as or different from each other and each represents an optionally substituted carbon atom, or an optionallysubstitutednitrogenatom, sulfuratomoroxygenatom, and Y optionally represents a single bond, and when Y represents the single bond, the ring to which X, Y and Z belong is a 5-membered ring; CyA represents a 5- to 14 membered non-aromatic cyclic amino groupornon-aromatic cyclic amidogroupwhichmaybe substituted, and the non-aromatic cyclic amino group or the non-aromatic cyclic amido group optionally having an oxygen atom or a sulfur atom; W represents a chain expressed by (1) optionally substituted -CH 2 -CH 2 -, (2) optionally substituted -CH=CH-, (3) -C-C-, (4) an optionally substituted phenylene group, (5) a single bond, (6) -NH-CO-, (7) -CO-NH-, (8) -NH-CH 2 -, (9) -CH 2 -NH-, (10) -CH 2 -CO-, (11) -CO-CH 2 -, (12) -O-(CH 2 ) m 1 (13) - (CH 2 ) -O- (where m represents an integer of 0 to 5), (14) -O-CH 2 -CR 2 =1 (15) -O-CH 2 -CHR 2 - (where R 2 represents a hydrogen atom, a C 16 alkyl group or a halogen atom), (16) -NH-S(O)l-, (17) -S(O)3l-NH-, (18) -CH 2 -S(°) 1 -. or (19) -S(O),-CH 2 - (where 1 represents 0, 1, or 2); and A represents a group having any of the following structural formulae: 2 (wherein R 3 and R 4 represent independently a hydrogen atom or an optionally substituted C 16 alkyl group, or combine through a carbon chain optionally containing a heteroatom to form a ring; R 5 and R 6 represent independently a hydrogen atom or an optionally substituted C 16 alkyl group, or combine through a carbon chain optionally containing a heteroatom to form a ring; R 7 represents a hydrogen atom, an optionally substituted C 16 alkyl group, a hydroxyl group, an alkoxy group, a halogen atom or an optionally substituted amino group; R 8 represents a hydrogen atom, a hydroxyl group, an alkoxy group, a halogen atom or an optionally substituted amino group; B1 represents an optionally substituted carbon atom, or an optionallysubstitutednitrogenatom, oxygenatomorsulfuratom; B2 represents an optionally substituted carbon atom or nitrogen atom; a and b represent an integer of 0 to 4, provided that a+b is an integer of 0 to 4; c represents 0 or 1; and 3 represents a single bond or a double bond, provided that when c is 1 in which A is a quinuclidine having R 8 represented by 4 the case where R 8 is a hydrogen atom or a hydroxyl group; Arl is an aromatic heterocycle; and W is one of (1) to (3), (6) to (11) and (16) to (19) are excluded).

  本发明提供了一种出色的角鲨烷合成酶抑制剂。具体地，提供了以下式子所表示的化合物（I），其盐或水合物。 其中，R1表示可以被取代的乙烯基或可以被取代的芳香环，n为0至2的整数；X、Y和Z相同或不同，每个表示可以被取代的碳原子、可以被取代的氮原子、硫原子或氧原子，Y可以表示单键，当Y表示单键时，X、Y和Z所属的环是一个五元环；CyA表示一个5-至14个成员的非芳香环状氨基团或非芳香环状酰胺基团，其可以被取代，非芳香环状氨基团或非芳香环状酰胺基团可以选择具有氧原子或硫原子；W表示由以下式子表示的链： （1）可以被取代的-CH2-CH2-， （2）可以被取代的-CH=CH-， （3）-C-C-， （4）可以被取代的苯基， （5）单键， （6）-NH-CO-， （7）-CO-NH-， （8）-NH-CH2-， （9）-CH2-NH-， （10）-CH2-CO-， （11）-CO-CH2-， （12）-O-（CH2）m1（其中m表示0至5的整数）， （13）-（CH2）-O-（其中m表示0至5的整数）， （14）-O-CH2-CR2=1， （15）-O-CH2-CHR2-（其中R2表示氢原子、C16烷基或卤素原子）， （16）-NH-S(O)l-， （17）-S(O)3l-NH-， （18）-CH2-S(°)1-或 （19）-S(O),-CH2-（其中l表示0、1或2）； A表示以下结构式之一的基团： （其中，R3和R4独立地表示氢原子或可以被取代的C16烷基，或通过可选含有杂原子的碳链结合形成环；R5和R6独立地表示氢原子或可以被取代的C16烷基，或通过可选含有杂原子的碳链结合形成环；R7表示氢原子、可以被取代的C16烷基、羟基、烷氧基、卤素原子或可以被取代的氨基团；R8表示氢原子、羟基、烷氧基、卤素原子或可以被取代的氨基团；B1表示可以被取代的碳原子、可以被取代的氮原子、氧原子或硫原子；B2表示可以被取代的碳原子或氮原子；a和b表示0至4的整数，前提是a+b是0至4的整数；c表示0或1；3表示单键或双键，当c为1时，A为具有R8由4表示的喹啉环的情况除外，Arl为芳香杂环，而W为（1）至（3）、（6）至（11）和（16）至（19）中的一种。
• CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS
  申请人：Kansas State University Research Foundation

  公开号：US20220204447A1

  公开（公告）日：2022-06-30

  Chiral polyvinylpyrrolidinone (CSPVP), complexes of CSPVP with a core species, such as a bimetallic nanocluster catalyst, and enantioselective oxidation reactions utilizing such complexes are disclosed. The catalytic complexes have exhibited the ability to achieve reaction products have a very high degree of optical purifies. These reaction products can be used as reagents in the synthesis of complex organic molecules, such as bioactive products, and C—H bond oxidation of complex molecules including various drugs and natural products.

  本发明公开了手性聚乙烯吡咯烷酮（CSPVP）及其与核心物种（例如双金属纳米簇催化剂）的配合物，以及利用这些配合物进行对映选择性氧化反应。这些催化配合物已经表现出实现反应产物具有非常高的光学纯度的能力。这些反应产物可用作复杂有机分子（如生物活性产物）的合成试剂，并用于包括各种药物和天然产物在内的复杂分子的C-H键氧化。
• N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1375496B1

  公开（公告）日：2007-07-04
• Chromium Iminoglycosylidenes: Synthesis and Application to Photoinduced C-Glycosidation
  作者：Karl Heinz Dötz、Markus Klumpe、Martin Nieger

  DOI：10.1002/(sici)1521-3765(19990201)5:2<691::aid-chem691>3.0.co;2-e

  日期：1999.2.1

  The iminoglycosylidene complexes 3a,b, 9, and 16a,b are conveniently prepared from the sugar lactams 2a,b, 8, and 15a,b by reaction with K2Cr(CO)(5) and subsequent deoxygenation with trimethylsilyl chloride (TMSCl). The Cr(CO)(5)-stabilized carbene moiety of the imino-D-ribo-pyranosylidene complexes 9 and 16a,b has been exploited in the photoinduced generation of ketene-like species on irradiation with UV light. These intermediates were trapped with methanol to produce the methyl 2,6-imino-D-allonates 10 and 17a,b. The C-glycosidation is p-selective and has been applied further to the preparation of the galactosyl 2,6-imino-D-allonate 19. Solvent effects suggest that the diastereoselectivity originates in the chromium fragment, which shields the re face of the proposed ketene intermediate.
• QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：Eisai Co., Ltd.

  公开号：EP1217001B1

  公开（公告）日：2005-12-07